MedTrace Logo

Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL

NCT03286400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2020-12-17

Study results available
· View outcomes & findings →

Summary

Collect real-world clinical and device-specific outcomes of the GORE® TAG® Conformable Thoracic Stent Graft featuring ACTIVE CONTROL System (CTAG Device with ACTIVE CONTROL) in the treatment of aortic disease as part of routine clinical practice.

Conditions

  • Thoracic Diseases

Interventions

DEVICE

CTAG Device with ACTIVE CONTROL

Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.

Sponsors & Collaborators

  • W.L.Gore & Associates

    lead INDUSTRY

Principal Investigators

  • Giovanni Torsello, MD, PhD · St Franziskus Hospital GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2019-10-09
Completion
2019-10-09

Countries

  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03286400 on ClinicalTrials.gov